The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

2015 has been quite an eventful year for the South Korean pharma industry, and was marked by a string of major international licensing agreements that may be looked back on as a watershed in the industry’s attempts to shift to original R&D. If you missed any of the major news and analysis from South Korea during the year, here's your opportunity to check out PharmAsia News' view of the most important stories.

Despite the challenges in the sector, South Korean biotech companies are making substantial progress in the gene and cell therapy space, with several companies set to begin or already in late stage clinical trials at home and abroad, stepping gradually towards commercialization.